Impax/GSK's Extended-Release Parkinson's Treatment IPX066 Aces Third Phase III Trial
Impax plans Q4 FDA submission, while GSK will approach European regulators in 2012.
Impax plans Q4 FDA submission, while GSK will approach European regulators in 2012.